Chastek B, et al. - This study is performed to investigate treatment persistence, cost, and cost per persistent patient among mechanism of action (MOA) switchers versus tumor necrosis factor inhibitor (TNFi) cyclers. According to the outcome obtained, MOA switching is related to higher treatment persistence and lower healthcare costs than TNFi cycling. Reimbursement policies that require patients to cycle TNFi before switching MOA may result in suboptimal outcomes for both patients and payers.